MedTrace Logo

To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea

NCT05867550 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2023-07-27

No results posted yet for this study

Summary

The goal of this clinical trial is to compare the efficacy of four different drugs in combination for management of irritable bowel syndrome (IBS)-associated diarrhea. The main question to answer is:

* Is there a significant difference in effect of different drug combinations in management of irritable bowel syndrome with diarrhea?

Participants will be divided into 3 treatment groups.

* Each group will be given a combination of drugs for 2 weeks
* At the end of study, efficacy of different drug combinations and their potential side effects will be compared between the treatment groups

Conditions

  • Irritable Bowel Syndrome With Diarrhea

Interventions

DRUG

Rifaximin 550 MG

Rifaximin 550 MG Oral Thrice Daily for 2 weeks will be included in all three treatment regimes i.e A, B and C

DRUG

Mebeverine 135 MG

Mebeverine 135 MG Oral Twice Daily for 2 weeks will be included in Group A Treatment Regimes

DRUG

Psyllium Husk

Psyllium Husk 15-35 MG Oral Once Daily for 2 weeks will be included in Group C Treatment Regimes

DRUG

Amitriptyline Hydrochloride 25 MG

Amitriptyline Hydrochloride 25 MG Oral Once Daily for 2 weeks will be included in Group B Treatment Regimes

Sponsors & Collaborators

  • Bahria University

    lead OTHER

Principal Investigators

  • Rashid Ali · Bahria University Health Science Campus Karachi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-03
Primary Completion
2023-03-27
Completion
2023-06-10

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05867550 on ClinicalTrials.gov